GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer
Coaching-based weight loss did not clearly cut breast cancer recurrence in BWEL, perhaps because the weight loss was too small. Drugs that produce three times as much weight loss could settle whether weight itself matters.
BWEL achieved modest weight loss with no clear iDFS effect. Bariatric surgery cohorts, with 25-30% weight loss, show large reductions in hormone-related cancers. GLP-1 receptor agonists sit between the two and are already widely used by breast cancer survivors off-trial; a randomised trial would answer the biological question BWEL could not and define safety alongside endocrine therapy (lean mass loss, bone density, gastrointestinal effects with CDK4/6 inhibitors).
- Survivorship and late effects are neglected · Tens of millions of people live after cancer with heart damage, infertility, second cancers and fear, and few services.
- Funding follows fashion, not burden · Money goes to the cancers and questions that are easy or popular, not the ones that kill most or where a dollar would do most.
Pages like this
not linked directly; found by shared links- PathwayLipid synthesis, uptake & cholesterol
Shares Body composition (lean mass, fat mass, visceral fat), Energy balance, Dietitian-led weight-loss programmes in HR-positive breast cancer, GLP-1 receptor agonists and obesity-related cancer risk.
- TrialWHEL (Women's Healthy Eating and Living)
Shares Energy balance, Dietitian-led weight-loss programmes in HR-positive breast cancer, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer.
- TechnologyStructured exercise programmes after curative treatment
Shares Energy balance, Dietitian-led weight-loss programmes in HR-positive breast cancer, Obesity-related cancers (IARC list of 13), Survivorship and late effects are neglected.
- PersonWendy Parulekar
Shares Letrozole (and other aromatase inhibitors), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TrialMONARCH 3
Shares Letrozole (and other aromatase inhibitors), Abemaciclib, HR-positive / HER2-negative breast cancer.
- IdeaLink bariatric and GLP-1 registries to cancer registries in every country that has both
Shares A trial of GLP-1 weight-loss drugs with cancer as the primary outcome, GLP-1 receptor agonists and obesity-related cancer risk, Obesity-related cancers (IARC list of 13).
- TermMetabolic syndrome and insulin resistance
Shares Energy balance, GLP-1 receptor agonists and obesity-related cancer risk, Obesity-related cancers (IARC list of 13).
- IdeaCardiometabolic screening and treatment for survivors on long-term hormone therapy
Shares Endocrine therapy (SERMs, AIs, SERDs), Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer.